Vaso Corp Narrows Q1 Net Loss to $887K; Revenue Flat, Adjusted for Divestiture
VASO sits 80% above its 52-week low of $0.105.
Summary
VASO Corp reported its first-quarter 2026 financial results, showing a narrowed net loss of $887 thousand, an improvement from $1.1 million in the prior year. Total revenue decreased slightly by 0.5% to $19.4 million, but increased by 4.8% when excluding the divested healthcare IT service business. Gross profit also improved by 1.9% to $11.6 million. While these results indicate some operational improvements, the company reported a significant increase in cash used in operating activities to $12.6 million, up from $566 thousand year-over-year, though management attributed this primarily to payment timing. This report provides the first look at the company's performance since its FY2025 10-K filing in March. Traders will be watching to see if the company can maintain its trend of narrowing losses and adjusted revenue growth, and if the cash flow issues are indeed temporary, as stated by management.
At the time of this announcement, VASO was trading at $0.19 on OTC in the Life Sciences sector, with a market capitalization of approximately $33.2M. The 52-week trading range was $0.11 to $0.22. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.